Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 99 articles: HTML format

Single Articles

January 2026
1. PRAUD D, Amadou A, Mercoeur B, Duboeuf M, et al
   Long-term atmospheric exposure to particulate matter and breast cancer risk: findings from a nested case-control study in France.
   Br J Cancer. 2026 Jan 13. doi: 10.1038/s41416-025-03311.
   PubMed     Abstract available
   
   
   
2. VALASAKI M, Taylor LC, Woof VG, Howell SJ, et al
   The breast cancer risk assessment pathway in England: a systems analysis of current challenges and ways to improve.
   Br J Cancer. 2026 Jan 6. doi: 10.1038/s41416-025-03329.
   PubMed     Abstract available
   
   
   
3. MICHAEL S, Broggio J, Bowers S, Ooi J, et al
   Distant recurrence and margin involvement in invasive breast cancer.
   Br J Cancer. 2026 Jan 5. doi: 10.1038/s41416-025-03275.
   PubMed     Abstract available
   
   
   
4. POURALI G, Matthew KA, Jeon MS, Luo C, et al
   Steroid hormone metabolites and mammographic breast density in premenopausal women.
   Br J Cancer. 2026;134:225-236.
   PubMed     Abstract available
   
   
   December 2025
5. DE SOUZA WAGNER PH, Matheus GTFU, Monteiro Ribeiro D, Figueroa Magalhaes MC, et al
   Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis.
   Br J Cancer. 2025 Dec 23. doi: 10.1038/s41416-025-03320.
   PubMed     Abstract available
   
   
   
6. GUPTA K, Koelsch N, Neely V, Graham L, et al
   Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.
   Br J Cancer. 2025 Dec 15. doi: 10.1038/s41416-025-03292.
   PubMed     Abstract available
   
   
   
7. MA J, Sun S, Tang X, Wang J, et al
   Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.
   Br J Cancer. 2025 Dec 9. doi: 10.1038/s41416-025-03287.
   PubMed     Abstract available
   
   
   
8. OH H, Yaghjyan L, Heng YJ, Baker GM, et al
   Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses' Health Study II.
   Br J Cancer. 2025;133:1695-1707.
   PubMed     Abstract available
   
   
   November 2025
9. VEIGA LHS, Gierach GL, Smith SA, Howell RM, et al
   Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors.
   Br J Cancer. 2025 Nov 14. doi: 10.1038/s41416-025-03240.
   PubMed     Abstract available
   
   
   
10. NOVITSKI SI, Jacobsen RL, Roder T, Holm PC, et al
    Breast cancer risk prediction with a modified BOADICEA model in Danish women.
    Br J Cancer. 2025 Nov 12. doi: 10.1038/s41416-025-03247.
    PubMed     Abstract available
    
    
    
11. COCCO P, Bojke C, Hulme C, Hall PS, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis.
    Br J Cancer. 2025 Nov 6. doi: 10.1038/s41416-025-03248.
    PubMed     Abstract available
    
    
    
12. KRAMER CJH, van Wijk LM, Ruano D, Gelpke-Vermeulen S, et al
    Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond.
    Br J Cancer. 2025;133:1199-1207.
    PubMed     Abstract available
    
    
    
13. ZUCKER K, McInerney C, Glaser A, Baxter P, et al
    Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.
    Br J Cancer. 2025;133:1137-1144.
    PubMed     Abstract available
    
    
    October 2025
14. RUIZ DE AZUA G, Licaj I, Pinto S, Havas J, et al
    Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study.
    Br J Cancer. 2025 Oct 21. doi: 10.1038/s41416-025-03238.
    PubMed     Abstract available
    
    
    
15. FUJII T, Iwase T, Shen Y, Fukui J, et al
    Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer.
    Br J Cancer. 2025 Oct 18. doi: 10.1038/s41416-025-03197.
    PubMed     Abstract available
    
    
    
16. FAN M, Wu X, Pan D, Du J, et al
    Multiscale Pancancer Analysis Uncovers Intrinsic Imaging and Molecular Characteristics Prominent in Breast Cancer and Glioblastoma.
    Br J Cancer. 2025 Oct 15. doi: 10.1038/s41416-025-03235.
    PubMed     Abstract available
    
    
    
17. CHEN X, Cao L, Feng M, Shuai Q, et al
    Breast cancer cell-derived adrenomedullin confers cancer-associated adipose remodeling through the cAMP/Creb1/Zeb1 axis.
    Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03219.
    PubMed     Abstract available
    
    
    
18. TUMANOVA K, Khorasani M, Nofech-Mozes S, Vitkin A, et al
    Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy.
    Br J Cancer. 2025 Oct 3. doi: 10.1038/s41416-025-03150.
    PubMed     Abstract available
    
    
    
19. LIU Y, Fan L, Ye F, Zhao Y, et al
    Androgen receptor interacts with c-Myc to regulate macrophage-osteoclast axis and drive bone metastasis in triple negative breast cancer.
    Br J Cancer. 2025 Oct 2. doi: 10.1038/s41416-025-03202.
    PubMed     Abstract available
    
    
    
20. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    PubMed     Abstract available
    
    
    
21. THONG MSY, Doege D, Koch-Gallenkamp L, Bertram H, et al
    Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.
    Br J Cancer. 2025;133:831-843.
    PubMed     Abstract available
    
    
    
22. LIANG H, Benard O, Kumar V, Griffen A, et al
    Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation.
    Br J Cancer. 2025;133:986-1002.
    PubMed     Abstract available
    
    
    September 2025
23. CUZICK J, Dowsett M
    Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.
    Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03115.
    PubMed     Abstract available
    
    
    
24. STEGGALL J, Rajeeve V, Al-Subaie N, Naeem A, et al
    Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer.
    Br J Cancer. 2025 Sep 13. doi: 10.1038/s41416-025-03174.
    PubMed     Abstract available
    
    
    
25. WOYTASH JA, Lefebvre AEYT, Zhang Z, Xu B, et al
    CDCP1/mitochondrial Src axis increases electron transport chain function to promote metastasis in triple-negative breast cancer.
    Br J Cancer. 2025 Sep 4. doi: 10.1038/s41416-025-03163.
    PubMed     Abstract available
    
    
    
26. WANG T, Zeleznik OA, McGee EE, Brantley KD, et al
    Prospective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women.
    Br J Cancer. 2025 Sep 4. doi: 10.1038/s41416-025-03159.
    PubMed     Abstract available
    
    
    
27. DUSTIN D, Gu G, Beyer AR, Herzog SK, et al
    Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
    Br J Cancer. 2025 Sep 1. doi: 10.1038/s41416-025-03096.
    PubMed    
    
    
    August 2025
28. WU Y, Zhou L, Zhao J, Peng Y, et al
    Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.
    Br J Cancer. 2025 Aug 26. doi: 10.1038/s41416-025-03146.
    PubMed     Abstract available
    
    
    
29. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03038.
    PubMed    
    
    
    
30. JING Y, Wu Y, Hu Q, Wu W, et al
    Remodelling hypoxic TNBC microenvironment restores antitumor efficacy of Vgamma9Vdelta2 T cell therapy.
    Br J Cancer. 2025;133:365-380.
    PubMed     Abstract available
    
    
    July 2025
31. HARVIE M, Pegington M, Howell A, Lim Y, et al
    Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer.
    Br J Cancer. 2025 Jul 31. doi: 10.1038/s41416-025-03129.
    PubMed     Abstract available
    
    
    
32. SOLMUNDE E, Pedersen RN, Norgaard M, Mellemkjaer L, et al
    Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up.
    Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03112.
    PubMed     Abstract available
    
    
    
33. FICORELLA L, Yang X, Mavaddat N, Carver T, et al
    Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117.
    PubMed     Abstract available
    
    
    
34. ALLEN G, Heiland EG, Teleka S, Glimelius I, et al
    Association of change in physical activity with use of outpatient specialist care and hospitalisations among breast cancer survivors with type 2 diabetes in Sweden.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03099.
    PubMed     Abstract available
    
    
    
35. SHIEN T, Hara F, Aogi K, Yanagida Y, et al
    Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03097.
    PubMed     Abstract available
    
    
    
36. FLAHERTY RL, Falcinelli M, Hesketh AR, Patel BA, et al
    Biomarkers of psychological stress are associated with increased susceptibility to the development of breast and prostate cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03085.
    PubMed     Abstract available
    
    
    June 2025
37. BARRAUD S, Vacher S, Schiffler C, Wong J, et al
    Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03083.
    PubMed     Abstract available
    
    
    
38. SCOTT OW, Tin Tin S, Cavadino A, Elwood JM, et al
    Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03070.
    PubMed     Abstract available
    
    
    May 2025
39. PIMENTEL-PARRA GA, Garcia-Vivar C, Escalada-Hernandez P, San Martin-Rodriguez L, et al
    Systematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations.
    Br J Cancer. 2025 May 17. doi: 10.1038/s41416-025-03059.
    PubMed     Abstract available
    
    
    
40. TYRAKIS PA, Kampjut D, Steele GF, Lindstrom HJG, et al
    Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
    Br J Cancer. 2025 May 13. doi: 10.1038/s41416-025-03035.
    PubMed     Abstract available
    
    
    
41. KOTSOPOULOS J, Maxwell CA, Lubinski J, Huzarski T, et al
    Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant.
    Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03029.
    PubMed     Abstract available
    
    
    
42. ABUDULA M, Astuti Y, Raymant M, Sharma V, et al
    Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA.
    Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03013.
    PubMed     Abstract available
    
    
    April 2025
43. PU Y, Xu F, He A, Li R, et al
    Repurposing chlorpromazine for the treatment of triple-negative breast cancer growth and metastasis based on modulation of mitochondria-mediated apoptosis and autophagy/mitophagy.
    Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02992.
    PubMed     Abstract available
    
    
    
44. PETERS J, van Leeuwen MM, Moriakov N, van Dijck JAAM, et al
    Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.
    Br J Cancer. 2025 Apr 6. doi: 10.1038/s41416-025-02995.
    PubMed     Abstract available
    
    
    
45. BUIJS SM, Jongbloed EM, van Bergen LEM, Ramakers CRB, et al
    Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.
    Br J Cancer. 2025;132:525-532.
    PubMed     Abstract available
    
    
    March 2025
46. CAIAZZA F, McGowan PM, Mullooly M, Murray A, et al
    Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
    Br J Cancer. 2025 Mar 14. doi: 10.1038/s41416-025-02973.
    PubMed    
    
    
    
47. SKRIVER C, Cronin-Fenton D, Borgquist S, Hansen Viuff J, et al
    Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study.
    Br J Cancer. 2025 Mar 8. doi: 10.1038/s41416-025-02974.
    PubMed     Abstract available
    
    
    
48. STEINDL A, Zach C, Berchtold L, Grisold A, et al
    Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.
    Br J Cancer. 2025 Mar 1. doi: 10.1038/s41416-025-02967.
    PubMed     Abstract available
    
    
    February 2025
49. ELLIOTT H, Allen AJ, Forester ND, Graziadio S, et al
    Women's perspectives of molecular breast imaging: a qualitative study.
    Br J Cancer. 2025;132:276-282.
    PubMed     Abstract available
    
    
    January 2025
50. VILLETTE CC, Dupuy N, Brightman FA, Zimmermann A, et al
    Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.
    Br J Cancer. 2025 Jan 28. doi: 10.1038/s41416-024-02935.
    PubMed     Abstract available
    
    
    December 2024
51. WU X, Ling Y, Zhang S, Zhang B, et al
    Advancing radiomics from contrast-enhanced mammography in breast cancer.
    Br J Cancer. 2024 Dec 12. doi: 10.1038/s41416-024-02932.
    PubMed    
    
    
    
52. WANG Q, Yu Y, Wang C, Jiang Z, et al
    Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer.
    Br J Cancer. 2024 Dec 10. doi: 10.1038/s41416-024-02917.
    PubMed     Abstract available
    
    
    November 2024
53. WANG W, Wang X, Jiang Y, Guo Y, et al
    Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.
    Br J Cancer. 2024 Nov 28. doi: 10.1038/s41416-024-02906.
    PubMed     Abstract available
    
    
    
54. LUIJENDIJK MJ, Buijs SM, Jager A, Koolen SLW, et al
    Effects of tamoxifen on cognitive function in patients with primary breast cancer.
    Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02914.
    PubMed     Abstract available
    
    
    
55. GIRITHAR HN, Krishnamurthy S, Carroll L, Guller A, et al
    Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02889.
    PubMed     Abstract available
    
    
    
56. SUN Y, Huo D
    Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02905.
    PubMed    
    
    
    
57. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Correction: Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Nov 11. doi: 10.1038/s41416-024-02886.
    PubMed    
    
    
    
58. KAUFMANN M, Vaysse PM, Savage A, Kooreman LFS, et al
    Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study.
    Br J Cancer. 2024;131:1298-1308.
    PubMed     Abstract available
    
    
    
59. TORR B, Jones C, Kavanaugh G, Hamill M, et al
    BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial.
    Br J Cancer. 2024;131:1506-1515.
    PubMed     Abstract available
    
    
    
60. WANG S, Wang T, Guo S, Zhu S, et al
    Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.
    Br J Cancer. 2024;131:1613-1622.
    PubMed     Abstract available
    
    
    October 2024
61. ZHAO T, Xu S, Ping J, Jia G, et al
    A proteome-wide association study identifies putative causal proteins for breast cancer risk.
    Br J Cancer. 2024 Oct 28. doi: 10.1038/s41416-024-02879.
    PubMed     Abstract available
    
    
    
62. EGELAND EV, Seip K, Skourti E, Oy GF, et al
    The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02875.
    PubMed     Abstract available
    
    
    
63. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Oct 7. doi: 10.1038/s41416-024-02846.
    PubMed     Abstract available
    
    
    
64. SABLIN MP, Gestraud P, Jonas SF, Lamy C, et al
    Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
    Br J Cancer. 2024;131:1060-1067.
    PubMed     Abstract available
    
    
    
65. CHIGUCHI G, Cho H
    What kind of tumour rupture requires adjuvant therapy?
    Br J Cancer. 2024;131:1109-1110.
    PubMed    
    
    
    September 2024
66. CASTRO-ESPIN C, Cairat M, Navionis AS, Dahm CC, et al
    Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
    Br J Cancer. 2024 Sep 28. doi: 10.1038/s41416-024-02858.
    PubMed     Abstract available
    
    
    
67. PRASAD D, Baldelli E, Blais EM, Davis J, et al
    Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.
    Br J Cancer. 2024 Sep 25. doi: 10.1038/s41416-024-02852.
    PubMed     Abstract available
    
    
    
68. PHILLIPS JB, Park SS, Lin CH, Cho J, et al
    SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer.
    Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02853.
    PubMed     Abstract available
    
    
    
69. JAVED SR, Skolariki A, Zameer MZ, Lord SR, et al
    Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
    Br J Cancer. 2024 Sep 9. doi: 10.1038/s41416-024-02833.
    PubMed     Abstract available
    
    
    
70. O'LEARY RL, Duijm LEM, Boersma LJ, van der Sangen MJC, et al
    Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.
    Br J Cancer. 2024;131:852-859.
    PubMed     Abstract available
    
    
    
71. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    PubMed     Abstract available
    
    
    
72. GRAFINGER OR, Hayward JJ, Meng Y, Geddes-McAlister J, et al
    Cancer cell extravasation requires (i)plectin-mediated delivery of MT1-MMP at invadopodia.
    Br J Cancer. 2024;131:931-943.
    PubMed     Abstract available
    
    
    August 2024
73. ARUN B, Couch FJ, Abraham J, Tung N, et al
    BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02827.
    PubMed     Abstract available
    
    
    
74. ZOU R, Loke SY, Tang YC, Too HP, et al
    Correction: Development and validation of a circulating microRNA panel for the early detection of breast cancer.
    Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02800.
    PubMed    
    
    
    
75. JOHNSON N, Bentley J, Wang LZ, Newell DR, et al
    Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
    Br J Cancer. 2024 Aug 19. doi: 10.1038/s41416-024-02813.
    PubMed    
    
    
    
76. YUAN J, Xiao M, Zheng Q
    Comment on: "A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures".
    Br J Cancer. 2024 Aug 1. doi: 10.1038/s41416-024-02807.
    PubMed    
    
    
    July 2024
77. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
    Correction: Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
    Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02791.
    PubMed    
    
    
    
78. BESSE A, Sedlarikova L, Buechler L, Kraus M, et al
    HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
    Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02774.
    PubMed     Abstract available
    
    
    
79. YAGHJYAN L, Heng YJ, Baker GM, Murthy D, et al
    Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.
    Br J Cancer. 2024;131:325-333.
    PubMed     Abstract available
    
    
    June 2024
80. POSSENTI I, Scala M, Carreras G, Bagnardi V, et al
    Exposure to second-hand smoke and breast cancer risk in non-smoking women: a comprehensive systematic review and meta-analysis.
    Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02732.
    PubMed     Abstract available
    
    
    
81. BOMAN C, Liu X, Eriksson Bergman L, Sun W, et al
    A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.
    Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02777.
    PubMed     Abstract available
    
    
    
82. ZHU T, Huang YH, Li W, Wu CG, et al
    A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02726.
    PubMed     Abstract available
    
    
    
83. POUMEAUD F, Morisseau M, Cabel L, Goncalves A, et al
    Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02766.
    PubMed     Abstract available
    
    
    
84. ZUO W, Wang Z, Qian J, Ma X, et al
    QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controll
    Br J Cancer. 2024 Jun 21. doi: 10.1038/s41416-024-02751.
    PubMed     Abstract available
    
    
    
85. RYU H, Shin KH, Chang JH, Jang BS, et al
    A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures.
    Br J Cancer. 2024 Jun 5. doi: 10.1038/s41416-024-02741.
    PubMed     Abstract available
    
    
    
86. TSOULAKI O, Tischkowitz M, Antoniou AC, Musgrave H, et al
    Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
    Br J Cancer. 2024;130:2027-2036.
    PubMed     Abstract available
    
    
    May 2024
87. TREEKITKARNMONGKOL W, Shah V, Kai K, Katayama H, et al
    Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
    Br J Cancer. 2024 May 17. doi: 10.1038/s41416-024-02697.
    PubMed     Abstract available
    
    
    
88. HAM B, Kim SY, Kim YA, Han D, et al
    Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02707.
    PubMed     Abstract available
    
    
    
89. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
    PubMed     Abstract available
    
    
    
90. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
    Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
    Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02703.
    PubMed     Abstract available
    
    
    
91. SHEN F, Jiang G, Philips S, Cantor E, et al
    Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
    Br J Cancer. 2024;130:1348-1355.
    PubMed     Abstract available
    
    
    
92. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    PubMed     Abstract available
    
    
    April 2024
93. HANNA D, Merrick S, Ghose A, Devlin MJ, et al
    Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02685.
    PubMed     Abstract available
    
    
    
94. CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al
    Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
    Br J Cancer. 2024 Apr 18. doi: 10.1038/s41416-024-02680.
    PubMed     Abstract available
    
    
    
95. BRAUN M, Piasecka D, Sadej R, Romanska HM, et al
    FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
    Br J Cancer. 2024 Apr 17. doi: 10.1038/s41416-024-02658.
    PubMed     Abstract available
    
    
    
96. ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
    Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
    PubMed     Abstract available
    
    
    
97. ALEXANDER J, Schipper K, Nash S, Brough R, et al
    Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
    PubMed     Abstract available
    
    
    March 2024
98. LIU X, Cheng X, Xie F, Li K, et al
    Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02610.
    PubMed     Abstract available
    
    
    
99. TEN VELDE DE, Duijm LEM, van der Sangen MJC, Schipper RJ, et al
    Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02633.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.